Advertisement
News
Advertisement

Aethlon Medical Releases Shareholder Letter

Wed, 04/06/2011 - 5:37am
Bio-Medicine.Org

SAN DIEGO, April 6, 2011 /PRNewswire/ -- Aethlon Medical, Inc., (OTCBB: AEMD) disclosed today that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.

(Photo:  http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

To our Shareholders:

On April 1st, we submitted a contract response to the Defense Advanced Research Projects Agency (DARPA) related to the Dialysis Like Therapeutics (DLT) program referenced in my last shareholder letter.  In our submission, we proposed to leverage our technology platform to deliver a dialysis-like therapy that would address precursors to sepsis, including bacterial toxins, viral pathogens, and disease enhancing particles transported by exosomes.  We believe our proposal meets goals underlying the DLT program as the resulting device would target to reduce the occurrence of sepsis and would provide decision-free and life saving medical care for the wounded warfighter.  Additionally, we introduced an innovative strategy to deliver our dialysis-like therapy without the need for anticoagulants, as well as a novel approach to selectively clear whole bacteria from circulation.  

If selected for an award, several larger organizations and industry thought leaders have agreed to partner with us to advance our program proposals.  It is anticipated that the DLT program awards will be announced in the next 120 days. We are now collaborating with our advisors to determine the next contract or grant opportunity to pursue. Beyond non-dilutive bioterror and pandemic threat funding opportunities, we are also evaluating potential responses to new government programs in Hepatitis-C, HIV, and Cancer.

In addition to navigating government funding opportunities, we are actively advancing research and clinical initiatives in both infectious disease and cancer.  On the clinical front, I am pleased to disclose that we our close to submitting our updated

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading